Results 151 to 160 of about 8,483 (184)
BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]
J Clin Exp HematopKojima K +4 more
europepmc +1 more source
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology. [PDF]
BMC Pharmacol ToxicolLi P +5 more
europepmc +1 more source
Integrated Genomic and GEO Data Analysis Reveals Therapeutic Targets for Rosacea. [PDF]
J Cosmet DermatolDeng X, He S, Long H, Xiao J, Xie Z.
europepmc +1 more source
Hemolytic Uremic Syndrome Complicated by Severe Neuropsychiatric Symptoms: A Case Report and Review of the Literature. [PDF]
CureusWang D, Wang W, Wang Y.
europepmc +1 more source
A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use. [PDF]
Sci RepZinzi A +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Neuroscience Nursing, 1992
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources